Tag: Zydus

Novel mechanism of targeting ‘hypoxia’ through HIF-PH inhibitor was studied for the first time in Hospitalised Covid-19 Patients in Mexico. Study trial indicates that the use of Desidustat for 14 days reduced CRP between baseline and day 14 among hospitalised patients with COVID-19.........................

The candidate has been supported by the National Biopharma Mission (NBM) under the aegis of BIRAC and the Department of Biotechnology, Government of India.......................

Phase I trial will study the safety, tolerability, pharmacokinetics and pharmacodynamics of ZYIL1 in healthy human volunteers. Zydus has secured a Strong IP portfolio with multiple patents filed in all major countries.....................

According to the company, Pegylated Interferon alpha – 2b significantly increased viral reduction and reduced the need for supplemental oxygen in moderate COVID-19 patients........................

Pegylated Interferon alpha – 2b significantly increased viral reduction and reduced the need for supplemental oxygen in moderate COVID-19 patients; the Company will now commence Phase III clinical trials..............

Vaccine Discovery Programme supported by the Department of Biotechnology, Govt. of India under the National Biopharma Mission, implemented by BIRAC moves into clinical trials The study will assess the safety, tolerability and immunogenicity of the vaccine.................

In a major breakthrough, Indian Council of Medical Research (ICMR)-National Institute of Virology (NIV) at Pune has developed and validated the indigenous IgG ELISA test for antibody detection for COVID-19. ICMR has also partnered with Zydus Cadila for mass-scale production of the ELISA test kits...................

Over 200 thought leaders from across India were involved in formulating the protocols of practice on endometriosis after a national meeting in Mumbai followed by regional meetings in major cities......................

The research partnership between Zydus Cadilla and Institute of Microbial Technology, will primarily aim to identify new drug candidates for treatment of drug-resistant infections...……….

Zyani1, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), is being tested as a viable treatment for anaemia associated with chronic kidney disease (CKD)...........